AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 102 min read$ONC

Ball Titus B. sold $37K of ONC

Ball Titus B. (Principal Accounting Officer) sold 136 shares of BeOne Medicines Ltd. (ONC) at an average of $271.33 ($271.06–$272.08) across 2 trades on 2026-06-08.

Original reporting
SEC EDGAR · Ball Titus B.
Published Jun 10, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
high confidence
Mentioned
$ONC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest concrete fact is the officer’s open-market sale and resulting zero-share holding; it can marginally influence sentiment but does not change the company’s fundamentals on its own.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no accompanying catalyst to drive a directional trade.

03

What to watch

The filing shows the officer ended with 0 shares, but it does not disclose reasons for the sale or any concurrent corporate developments; without additional news, signal-to-noise is low.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10; sale executed 2026-06-08.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralHigh confidence
Context

BeOne Medicines (ONC) disclosed an insider open-market sale by its principal accounting officer: 136 shares sold at ~$271.33 on 2026-06-08, leaving 0 shares.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other new company-specific news.

Evidence & confidence

The filing is an ownership-change event without accompanying guidance, trial, deal, or regulatory updates; insider sales are often non-informational, and the disclosed size is modest ($36.9k).

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was reportedly not under a 10b5-1 plan, some traders may over-interpret it; however, Form 4 sales frequently reflect diversification, taxes, or scheduled liquidity needs rather than negative fundamentals.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Subject of the SEC Form 4 insider transaction (ONC).

  • insider
    Ball Titus B.

    Principal Accounting Officer who sold 136 shares in two trades on 2026-06-08.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min